Analysis of Monoclonal Antibodies and Antibody Drug Conjugates (ADCs)
Monoclonal antibodies (mAbs) have emerged as revolutionary therapeutic agents for an array of human diseases. In addition to their large mass and complex structure, mAbs are varied in their origin, makeup, effector function and delivery, and therefore require thorough formulation development, including characterization, quantitation and preservation.
More and more special designed Antibody drug conjugates (ADCs) are under development as targeted therapy for treating cancer. ADCs combine the targeting capabilities of monoclonal antibodies with the cancer-killing ability of cytotoxic drugs.